What a difference a year can make.  The three

What a difference a year can make.  The three pharma companies referenced below all demonstrated increased revenues as a result of drug launches and excellent marketing strategies during this past year. Check this out, GSK (Glaxo) last March had a PPS of 45.32, grew 23% to 55.89.  Amgen went from 85.13 a year ago to 123.84, a 45% increase, and Jazz went from 55.25 a year ago to 169.11, an incredible 200% increase in PPS.  All three of these companies started out very small many years ago, had a solid & realistic vision for the future, and implemented a business plan/strategy that accurately addressed the marketplace where they competed. Also, during their infancy, each of these companies had a CORE group of investors who believed and stuck with these companies during their developmental stages. Plus, one other aspect of doing business these three shared along the way to their stardom was that they all had challenges and disappointments along the way.  Each dealt with delayed or failed new product launches, levied fines by the FDA for inappropriate promotion, generic intrusion, and Wall Street experts who questioned their strategies, all of which impacted their revenues and PPS. Does this sound familiar? Well, it should. Mr. Bob Schneiderman created SCRC, a small company with a realistic vision for the future, and is implementing a business plan/model which will eventually impact the OTC marketplace across the U.S. and several continents. Is Bob facing challenges and disappointments along the way to seeing ScripsAmerica reach its deserved stardom? He sure is, and we have seen and felt it in the current PPS these last few months. But Bob keeps moving forward as any good CEO would. He is focused on the future and chooses to ignore the so called experts (bashers). Plus, like the three big pharma companies listed above, SCRC has us, the CORE group of investors, who believe and who will stick by Bob throughout SCRC’s infancy. Oh, I will admit, I lose my patience at times, and a few of you unfortunately have to endure my PMs, but my belief in SCRC never wavers. When comparing SCRC to these three big Pharma giants, what I see is they share the same ingredients for success. “What a difference a year made”, that’s what we will be saying to each when we see SCRC reach its full potential. It’s my absolute pleasure to be associated with this CORE group of investors and I look forward to traveling to Tuscany in the Summer of 2015 to share SCRC’s success with all of you who can join us.